AI
Friday, October 08, 2010 9:58:27 AM
There is speculation that MNTA’s growing heparin characterization patent estate may enjoin Teva from commercializing a generic enox despite FDA approval.
I like that part.
In fact, I suggested it (on this board) before anyone else that I know of.
The problem of proof will be difficult, as will applicability of the patents.
ij
There are times when rules and precedents cannot be broken; others when they cannot be adhered to with safety. (Thomas Joplin)
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
